ARS Pharmaceuticals, Inc. SPRY revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ARS Pharmaceuticals, Inc. reported revenue across 3 products and services; the largest, Product, was $72.2M, 85.7% of the filed sum (+895.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$72.2M85.7%+895.1% yoy
- Revenue Under Collaboration Agreements$9.72M11.5%-88.1% yoy
- Revenue Under Supply Agreements$2.37M2.8%+549.3% yoy
Members sum to the consolidated $84.3M for this period.
- United States$72.2M85.7%+895.1% yoy
- Outside the United States$12.1M14.3%-85.2% yoy
Members sum to the consolidated $84.3M for this period.
- Product$17.5M76.9%+124.8% yoy
- Revenue Under Supply Agreements$2.74M12.1%no prior
- Revenue Under Collaboration Agreements$2.49M11.0%+1085.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.